Featured Posters & Presentations
Lyfgenia
Resolution of serious vaso-occlusive pain crises and reduction in patient-reported pain intensity: results from the ongoing Phase 1 /2 HGB-206 Group C Study of LentiGlobin for sickle cell disease (bb1111 ) gene therapy.
Authors: Kwiatkowski JL
Lyfgenia
Complications of sickle cell disease in East London Newborn Cohort patients over the years 2015-2018.
Authors: Soriano M.
Zynteglo
Restoring iron homeostasis in patients who achieved transfusion independence after treatment with betibeglogene autotemcel gene therapy: results from up to 7 years of follow-up.
Authors: Thompson AA.
Zynteglo
Betibeglogene autotemcel in patients with transfusion-dependent β-thalassemia: updated results from HGB-207 (Northstar-2) and HGB-212 (Northstar-3).
Authors: Locatelli F.